1252 related articles for article (PubMed ID: 23395909)
1. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
2. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Waldhauer I; Steinle A
Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
[TBL] [Abstract][Full Text] [Related]
3. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
[TBL] [Abstract][Full Text] [Related]
4. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
5. Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
Giuliani E; Vassena L; Cerboni C; Doria M
Curr Drug Targets; 2016; 17(1):54-64. PubMed ID: 26122035
[TBL] [Abstract][Full Text] [Related]
6. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway.
Le Maux Chansac B; Missé D; Richon C; Vergnon I; Kubin M; Soria JC; Moretta A; Chouaib S; Mami-Chouaib F
Int Immunol; 2008 Jul; 20(7):801-10. PubMed ID: 18441340
[TBL] [Abstract][Full Text] [Related]
8. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
9. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
Front Immunol; 2018; 9():1282. PubMed ID: 29963042
[TBL] [Abstract][Full Text] [Related]
10. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.
Chitadze G; Bhat J; Lettau M; Janssen O; Kabelitz D
Scand J Immunol; 2013 Aug; 78(2):120-9. PubMed ID: 23679194
[TBL] [Abstract][Full Text] [Related]
11. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
[TBL] [Abstract][Full Text] [Related]
12. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
13. NKG2D ligands expression and NKG2D-mediated NK activity in Sezary patients.
Dulphy N; Berrou J; Campillo JA; Bagot M; Bensussan A; Toubert A
J Invest Dermatol; 2009 Feb; 129(2):359-64. PubMed ID: 18754036
[TBL] [Abstract][Full Text] [Related]
14. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
[TBL] [Abstract][Full Text] [Related]
15. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells.
Cerboni C; Ardolino M; Santoni A; Zingoni A
Blood; 2009 Mar; 113(13):2955-64. PubMed ID: 19124832
[TBL] [Abstract][Full Text] [Related]
16. Altered NK-cell compartment and dysfunctional NKG2D/NKG2D-ligand axis in patients with ataxia-telangiectasia.
Desimio MG; Finocchi A; Di Matteo G; Di Cesare S; Giancotta C; Conti F; Chessa L; Piane M; Montin D; Dellepiane M; Rossi P; Cancrini C; Doria M
Clin Immunol; 2021 Sep; 230():108802. PubMed ID: 34298181
[TBL] [Abstract][Full Text] [Related]
17. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.
Wittenbrink M; Spreu J; Steinle A
Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.
Hilpert J; Grosse-Hovest L; Grünebach F; Buechele C; Nuebling T; Raum T; Steinle A; Salih HR
J Immunol; 2012 Aug; 189(3):1360-71. PubMed ID: 22730533
[TBL] [Abstract][Full Text] [Related]
19. Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell.
Bae DS; Hwang YK; Lee JK
Cell Immunol; 2012; 276(1-2):122-7. PubMed ID: 22613008
[TBL] [Abstract][Full Text] [Related]
20. Corticotropin-releasing factor induces immune escape of cervical cancer cells by downregulation of NKG2D.
Song H; Park H; Park G; Kim YS; Lee HK; Jin DH; Kang HS; Cho DH; Hur D
Oncol Rep; 2014 Jul; 32(1):425-30. PubMed ID: 24841552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
